iDEL Therapeutics GmbH | $10,381,635 | (Mar 18, 2026)
Surf AI(1) | $57,000,000 | (Mar 18, 2026)
R1 Therapeutics | $77,500,000 | (Mar 18, 2026)
Certified by Founder
Lodge
Mubadala Capital
investor
United Arab Emirates
- Abu Dhabi
- 09/11/2022
- Series B
- $70,000,000
Mubadala Capital is the wholly owned asset management arm of Mubadala Investment Company. Since its inception a decade ago, Mubadala Capital has grown to become a global asset manager of significant scale, with over US $16 billion of assets under management and a presence in London, New York, San Francisco, Rio de Janeiro, and headquarters in Abu Dhabi.
Through its four businesses, Mubadala Capital manages over US $11 billion in third-party capital vehicles on behalf of its institutional investors, including three private equity funds, two early stage venture funds, a public equities fund, and two funds in Brazil focused on special situations.
- Industry Venture Capital and Private Equity Principals
- Website https://www.mubadala.com/en/what-we-do/mubadala-capital
- LinkedIn https://www.linkedin.com/company/mubadala-capital/
Quorus | $5,000,000 | (Mar 18, 2026)
BambooBox | $6,600,000 | (Mar 18, 2026)
Conduit Health | $17,000,000 | (Mar 18, 2026)
SEQUENTIAL | $3,500,000 | (Mar 18, 2026)
Standard Template Labs | $49,000,000 | (Mar 18, 2026)
Tenkara | $7,000,000 | (Mar 18, 2026)
Turquoise(US) | $40,000,000 | (Mar 18, 2026)
Malama Health | $9,200,000 | (Mar 17, 2026)
AgZen | $10,000,000 | (Mar 17, 2026)